Glenmark Pharma gets US FDA approval for zolmitriptan pill

26 Sep 2011 Evaluate

Glenmark Pharmaceuticals has got a tentative approval from the US Food and Drug Administration (US FDA) for its zolmitriptan pill, the generic version of AstraZeneca Plc.’s Zomig anti-migraine medicine.

Earlier in August, Glenmark Pharmecuaticals’ novel chemical entity “Revamilast” initiated Phase II B human dose range finding trial globally. Revamilast is an orally active, potent and selective inhibitor of phosphodiesterase 4 (PDE 4) that is currently being developed by Glenmark for the treatment of chronic inflammatory disorders such as Asthma, Rheumatoid Arthritis (RA) and other inflammatory diseases.

Glenmark Pharmecuaticals is research driven globally integrated pharmaceuticals company headquartered in Mumbai. It is leading player in the discovery of new molecules both NCEs (New chemical entity) and NBEs (New biological entity).

Glenmark Pharma Share Price

2025.40 -10.50 (-0.52%)
01-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1720.40
Dr. Reddys Lab 1253.60
Cipla 1500.10
Zydus Lifesciences 914.50
Lupin 2103.30
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×